Intensive Blood Pressure Management Reduces CVD Risk in Type 2 Diabetes Patients
An intensive treatment approach to lower high systolic blood pressure (SBP) has shown a significant reduction in cardiovascular disease (CVD) risk for adults with type 2 diabetes (T2D). This finding comes from the Blood Pressure Control Target in Diabetes (BPROAD) Study presented at the American Heart Association (AHA) Scientific Sessions 2024.
The study involved nearly 13,000 adults with T2D and high SBP. Researchers aimed to see how reducing SBP to ≤120 mmHg affects major cardiovascular events, including non-fatal heart attacks, strokes, heart failure hospitalizations, or deaths due to CVD.
Lead investigator Guang Ning emphasized that lowering SBP to under 120 mmHg significantly reduces the risk of major cardiovascular events for most adults with T2D. Nearly 75% of adults with T2D have high blood pressure. Managing blood pressure is crucial to reducing cardiovascular risks.
The BPROAD study recruited 12,821 participants from 145 sites across China, averaging 64 years old, with around 45% being women. About half of them received intensive treatment aimed at achieving ≤120 mmHg, while the other half followed a standard treatment targeting ≤140 mmHg.
– How does blood pressure management impact the risk of cardiovascular events in patients with type 2 diabetes?
Interview with Dr. Guang Ning: Exploring the Impact of Intensive Blood Pressure Treatment in Adults with Type 2 Diabetes
By News Directory 3 Staff Writer
News Directory 3: Thank you for joining us today, Dr. Ning. Your recent study, the Blood Pressure Control Target in Diabetes (BPROAD), presents compelling findings regarding blood pressure management in adults with type 2 diabetes (T2D). Can you summarize the significance of your research?
Dr. Guang Ning: Thank you for having me. Our study demonstrates that intensive treatment aiming to lower systolic blood pressure (SBP) to ≤120 mmHg can significantly reduce the risk of major cardiovascular events in adults with T2D. Since nearly 75% of people with T2D have elevated blood pressure, effective management is crucial for mitigating cardiovascular disease (CVD) risks.
News Directory 3: The study involved nearly 13,000 participants. Can you explain the methodology and the outcomes you observed between the intensive treatment group and the standard treatment group?
Dr. Guang Ning: Absolutely. We recruited 12,821 participants across 145 sites in China, with an average age of 64 years and roughly 45% being women. The participants were divided into two groups: one received intensive treatment targeting SBP ≤120 mmHg, while the other adhered to standard treatment targeting ≤140 mmHg. We found that only 1.65% of the intensive group experienced non-fatal strokes, heart attacks, hospitalizations for heart failure, or cardiovascular death, compared to 2.09% in the standard group.
News Directory 3: Those are significant results. Were there any notable differences in adverse events between the two groups?
Dr. Guang Ning: Yes, while serious adverse events were generally similar, we did observe a higher incidence of symptomatic hypotension and hyperkalemia in the intensive treatment group. This highlights the need for careful monitoring, but the overall benefits in reducing CVD events were clear.
News Directory 3: Understanding these risks is essential. How do you envision these findings influencing future clinical guidelines for the treatment of hypertension in T2D patients?
Dr. Guang Ning: I believe our findings should encourage a reevaluation of current clinical guidelines. We hope to identify more patients who could benefit from intensive blood pressure management and ensure that healthcare providers are aware of the potential for reduced cardiovascular risks associated with lowering SBP to ≤120 mmHg.
News Directory 3: As a final thought, what message would you like to convey to both patients with T2D and healthcare professionals regarding blood pressure management?
Dr. Guang Ning: I urge both patients and healthcare professionals to prioritize blood pressure management as an integral part of T2D care. Effective control of SBP can dramatically lower the risk of serious cardiovascular events, ultimately improving health outcomes and quality of life for many individuals with diabetes.
News Directory 3: Thank you, Dr. Ning, for your insights and for discussing this crucial topic. We look forward to seeing how your research will shape future practices in diabetes care.
Dr. Guang Ning: Thank you for the opportunity to share our findings.
Over the study, 1.65% of those in the intensive group experienced non-fatal strokes, heart attacks, hospitalizations for heart failure, or cardiovascular death, compared to 2.09% in the standard group. While serious adverse events were similar between the groups, the intensive treatment group experienced more cases of symptomatic hypotension and hyperkalemia.
Ning noted that these results align with previous studies involving patients without hypertension. He hopes future clinical guidelines will reflect these findings and help identify those who would benefit most from intense blood pressure treatments.
These results highlight the importance of effective blood pressure management in preventing cardiovascular complications among people with T2D.